These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36824451)

  • 41. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications.
    Nägele MP; Haubner B; Tanner FC; Ruschitzka F; Flammer AJ
    Atherosclerosis; 2020 Dec; 314():58-62. PubMed ID: 33161318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter Ozone Study in oldEr Subjects (MOSES): Part 1. Effects of Exposure to Low Concentrations of Ozone on Respiratory and Cardiovascular Outcomes.
    Frampton MW; Balmes JR; Bromberg PA; Stark P; Arjomandi M; Hazucha MJ; Rich DQ; Hollenbeck-Pringle D; Dagincourt N; Alexis N; Ganz P; Zareba W; Costantini MG
    Res Rep Health Eff Inst; 2017 Jun; 2017(192, Pt 1):1-107. PubMed ID: 31898880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracorporeal lung support technologies - bridge to recovery and bridge to lung transplantation in adult patients: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(5):1-47. PubMed ID: 23074408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome.
    Galvin IM; Steel A; Pinto R; Ferguson ND; Davies MW
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD003707. PubMed ID: 23881653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between the structure, function and endothelial damage, and vascular ageing and the biopsychological situation in adults diagnosed with persistent COVID (BioICOPER study). A research protocol of a cross-sectional study.
    Gómez-Sánchez L; Tamayo-Morales O; Suárez-Moreno N; Bermejo-Martín JF; Domínguez-Martín A; Martín-Oterino JA; Martín-González JI; González-Calle D; García-García Á; Lugones-Sánchez C; González-Sánchez S; Jiménez-Gómez R; García-Ortiz L; Gómez-Marcos MA; Navarro-Matías E;
    Front Physiol; 2023; 14():1236430. PubMed ID: 37772064
    [No Abstract]   [Full Text] [Related]  

  • 46. Pathophysiological mechanisms of thrombosis in acute and long COVID-19.
    Jing H; Wu X; Xiang M; Liu L; Novakovic VA; Shi J
    Front Immunol; 2022; 13():992384. PubMed ID: 36466841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
    Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
    Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?
    Ghasemzadeh M; Ahmadi J; Hosseini E
    Thromb Res; 2022 May; 213():179-194. PubMed ID: 35397313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).
    Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á
    Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review.
    Riou M; Coste F; Meyer A; Enache I; Talha S; Charloux A; Reboul C; Geny B
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations.
    Karim S; Islam A; Rafiq S; Laher I
    Trop Med Infect Dis; 2021 Feb; 6(1):. PubMed ID: 33670475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombotic risk in children with COVID-19 infection: A systematic review of the literature.
    Zaffanello M; Piacentini G; Nosetti L; Ganzarolli S; Franchini M
    Thromb Res; 2021 Sep; 205():92-98. PubMed ID: 34293539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications.
    Vrints CJM; Krychtiuk KA; Van Craenenbroeck EM; Segers VF; Price S; Heidbuchel H
    Acta Cardiol; 2021 Apr; 76(2):109-124. PubMed ID: 33208052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
    Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
    Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
    Obi AT; Barnes GD; Napolitano LM; Henke PK; Wakefield TW
    J Vasc Surg Venous Lymphat Disord; 2021 Jan; 9(1):23-35. PubMed ID: 32916371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: Impact on Disease Severity.
    De Lorenzo A; Estato V; Castro-Faria-Neto HC; Tibirica E
    J Inflamm Res; 2021; 14():2267-2276. PubMed ID: 34079332
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurological Sequelae of COVID-19.
    Ahmad SJ; Feigen CM; Vazquez JP; Kobets AJ; Altschul DJ
    J Integr Neurosci; 2022 Apr; 21(3):77. PubMed ID: 35633158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Down-regulation of vascular PPAR-γ contributes to endothelial dysfunction in high-fat diet-induced obese mice exposed to chronic intermittent hypoxia.
    Zhang Y; Zhang C; Li H; Hou J
    Biochem Biophys Res Commun; 2017 Oct; 492(2):243-248. PubMed ID: 28822761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.